Stemtech

Stemtech Free Cash Flow

The Free Cash Flow (FCF) of Stemtech (STEK) as of Nov 4, 2026 is -483,583.00 USD. In the previous year, Free Cash Flow (FCF) was -601,198.00 USD — a change of -19.56% (higher).

Free Cash Flow

-483,583.00USD

YoY

-19.56%

Last updated:

Free Cash Flow (FCF) of Stemtech is 2025 -483,583.00 USD. Free Cash Flow (FCF) of Stemtech was 2024 -601,198.00 USD. It decreases by -19.56% higher compared to the previous year.

The Stemtech Free Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Free Cash Flow
Date
Free Cash Flow
Jan 1, 2018
-25,351.00 USD
Jan 1, 2019
-56,570.00 USD
Jan 1, 2020
-278,315.00 USD
Jan 1, 2021
-1.91 M USD
Jan 1, 2022
-1.22 M USD
Jan 1, 2023
-2.04 M USD
Jan 1, 2024
-601,198.00 USD
Jan 1, 2025
-483,583.00 USD
The Stemtech Free Cash Flow history
YEARFree Cash FlowYoY
-483,583.00USD-19.56%
-601,198.00USD-70.47%
-2.04 MUSD+67.30%
-1.22 MUSD-36.42%
-1.91 MUSD+587.74%
-278,315.00USD+391.98%
-56,570.00USD+123.15%
-25,351.00USD+2.06%
-24,839.00USD-34.00%
-37,635.00USD+118.21%
-17,247.00USD-45.57%
-31,687.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Stemtech Stock analysis

What does Stemtech do? Stemtech Corp develops nutritional supplements that support stem cell activity, marketed internationally through subsidiaries and independent distributors. The company's products include the RCM System, stemrelease3, Stemflo MigraStem, OraStem for oral health, and D-Fuze for electromagnetic frequency blocking. Cellect One Rapid Renew Stem Cell Peptide Night Cream is its skincare offering. Products are sold in North America, Latin America, and Asia through distributors and subsidiaries. The firm's brands target health-conscious consumers seeking stem cell support, with OraStem focusing on oral care and D-Fuze addressing electromagnetic frequency concerns. Independent distributors handle sales across all segments, leveraging the company's international presence. The RCM System and stemrelease3 are core products for general stem cell enhancement. Stemtech Corp's revenue streams come from direct sales of its branded nutritional supplements and skincare products. Distributors purchase products from subsidiaries to resell, generating consistent income through these channels. The company's international segments ensure diverse market coverage without relying on a single region. Stemtech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stemtech stock

Free Cash Flow (FCF) of Stemtech is -483,583.00 USD in 2025.

Free Cash Flow (FCF) of Stemtech changed from -601,198.00 USD to -483,583.00 USD, representing a -19.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow (FCF) Stemtech since 2006 – with annual values, charts, and detailed analysis.

Free Cash Flow is the cash available after capital expenditures. It represents the cash a company can use for dividends, debt reduction, or reinvestment.

FCF = Operating Cash Flow - Capital Expenditures

Free Cash Flow (FCF)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Free Cash Flow (FCF)'s Stemtech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Stemtech

All Key Metrics — Stemtech